Dave Fornell, DAIC Editor

Dave Fornell, Editor DAIC

Blog | Dave Fornell, DAIC Editor | March 25, 2014

Key Technologies Highlighted as Late-Breakers at ACC.14

By Dave Fornell, DAIC editor

Data from several cutting-edge device clinical trials will be presented as late-breakers at the American College of Cardiology 63rd Annual Scientific Session & Expo (ACC.14), March 28-31.  

One of the most anticipated therapies on the interventional front is the use of renal denervation to treat drug resistant hypertension. However, its future was called into question recently when Medtronic announced it failed to meet the primary endpoints in its SYMPLICITY HTN-3 U.S. pivotal trial. The results of that trial will be presented at ACC on Saturday. Experts say this is not the end of the story, and additional data might be revealed in another late-breaker with data from the Global SYMPLICITY Registry. 

Also on the interventional front, the NEXT trial is among the first to compare a biodegradable polymer drug-eluting stent (DES) with a durable polymer DES. 

In electrophysiology, the use of cardiac resynchronization therapy (CRT) devices was expanded a few years ago to patients with mild heart failure. One of the late breakers will discuss long-term survival in this CRT population.

In structural heart, three key presentations are featured. The CHOICE Trial will compare self-expanding (Medtronic’s Corevalve) to balloon expandable (Edwards’ Sapien) TAVR devices. Another compares the Corevalve with surgical outcomes in patients deemed high risk for surgery. The final session will share one-year outcomes from the STS/ACC Transcatheter Valve Therapy Registry.

Complete list of ACC late-breaking trials

For information on ACC.14, the official site is accscientificsession.cardiosource.org 

Related Content

Edwards Intuity aortic valve, surgical aortic valve replacement, PinnacleHealth, first U.S. implants
News | Heart Valve Technology| August 26, 2016
This week, PinnacleHealth, Harrisburg, Pa., became the first hospital in the country to implant the Edwards Intuity...
cardiac surgery, simulation training, University of Washington, case studies

Multiple repetitions of bypass grafts on a heart, using the Ramphal simulator. Courtesy of the University of Washington in Seattle.

News | Cardiovascular Surgery| August 25, 2016
August 25, 2016 — Simulation training fo
aortic dissection, family history, same age, clinical study, John A. Elefteriades, Annals of Thoracic Surgery
News | Structural Heart| August 25, 2016
People with a family member who had an aortic dissection — a spontaneous tear in one of the body’s main arteries —...
nanoparticles, blood clotting, internal bleeding, American Chemical Society study, Erin B. Lavik

Nanoparticles (green) help form clots in an injured liver. The researchers added color to the scanning electron microscopy image after it was taken. Image courtesy of Erin Lavik, Ph.D.

News | Hemostasis Management| August 24, 2016
August 24, 2016 — Whether severe trauma occurs on the battlefield or the highway, saving lives often comes down to...
Intact Vascular, TOBA clinical study, one-year results, Tack Endovascular System, Journal of Vascular Surgery
News | Peripheral Arterial Disease (PAD)| August 24, 2016
Intact Vascular Inc. announced that the one-year results from its Tack Optimized Balloon Angioplasty (TOBA) clinical...
Technavio report, renal denervation devices, 2015
News | Renal Denervation| August 23, 2016
August 23, 2016 — Technavio analysts forecast the global...
News | Heart Failure| August 23, 2016
August 23, 2016 — A new study of more than 13,000 people has found that so-called morbid obesity appears to stand alo
Jason Burdick, injectable hydrogels, heart failure, heart attack, American Chemical Society

Compared to other types of hydrogels being developed (left), a new hydrogel (right) can form crosslinks after injection into the heart, making the material stiffer and longer-lasting. Image courtesy of American Chemical Society.

News | Heart Failure| August 23, 2016
August 23, 2016 — During a heart attack, clots or narrowed arteries block blood flow, harming or killing cells within
News | Peripheral Arterial Disease (PAD)| August 22, 2016
Avinger Inc. recently announced the closing of its previously announced public offering of 9,857,800 shares of Avinger’...
sleep apnea, hypertension, clinical study, Science Signaling, University of Chicago
News | Hypertension| August 22, 2016
Obstructive sleep apnea is a common cause of high blood pressure. In the Aug. 17, 2016, issue of the journal Science...
Overlay Init